Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Amicus Therapeutics (FOLD) Return on Capital Employed (2016 - 2025)

Historic Return on Capital Employed for Amicus Therapeutics (FOLD) over the last 17 years, with Q3 2025 value amounting to 0.05%.

  • Amicus Therapeutics' Return on Capital Employed rose 400.0% to 0.05% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.05%, marking a year-over-year increase of 400.0%. This contributed to the annual value of 0.04% for FY2024, which is 1700.0% up from last year.
  • Latest data reveals that Amicus Therapeutics reported Return on Capital Employed of 0.05% as of Q3 2025, which was up 400.0% from 0.03% recorded in Q2 2025.
  • In the past 5 years, Amicus Therapeutics' Return on Capital Employed registered a high of 0.07% during Q1 2025, and its lowest value of 0.39% during Q3 2022.
  • For the 5-year period, Amicus Therapeutics' Return on Capital Employed averaged around 0.18%, with its median value being 0.24% (2023).
  • Per our database at Business Quant, Amicus Therapeutics' Return on Capital Employed crashed by -1300bps in 2022 and then skyrocketed by 2200bps in 2023.
  • Amicus Therapeutics' Return on Capital Employed (Quarter) stood at 0.26% in 2021, then plummeted by -34bps to 0.35% in 2022, then skyrocketed by 64bps to 0.13% in 2023, then surged by 131bps to 0.04% in 2024, then skyrocketed by 31bps to 0.05% in 2025.
  • Its Return on Capital Employed stands at 0.05% for Q3 2025, versus 0.03% for Q2 2025 and 0.07% for Q1 2025.